|
Immune cells in primary tumor
|
|
CD3
|
>3.04 (n = 16) vs. ≤ 3.04 (n = 16)
|
85% vs. 67%
|
0.4
|
|
CD8
|
>2.49(n = 16) vs. ≤ 2.49(n = 16)
|
79% vs. 69%
|
0.29
|
|
FoxP3
|
>1.81 (n = 17) vs. ≤ 1.81(n = 15)
|
86% vs. 63%
|
0.27
|
|
CD20
|
>0.23 (n = 18) vs. ≤ 0.23(n = 13)
|
83% vs. 81%
|
0.8
|
|
CD68
|
>1.02 (n = 16) vs. ≤ 1.02(n = 16)
|
73% vs. 75%
|
0.8
|
|
Granzyme B
|
>0 (n = 18) vs. = 0(n = 15)
|
82% vs. 68%
|
0.53
|
|
Intraepithelial immune cells in metastatic lymph nodes
|
|
CD3
|
>3.52 (n = 13) vs. ≤ 3.52 (n = 14)
|
77% vs. 62%
|
0.26
|
|
CD8
|
>1.29 (n = 14) vs. ≤ 1.29 (n = 14)
|
91% vs. 53%
|
0.07
|
|
FoxP3
|
>2.26 (n = 14) vs. ≤ 2.26 (n = 13)
|
84% vs. 53%
|
0.17
|
|
CD20
|
>1.76 (n = 12) vs. ≤ 1.76 (n = 11)
|
82% vs. 60%
|
0.29
|
|
CD68
|
>1.05 (n = 14) vs. ≤ 1.05 (n = 13)
|
67% vs.73%
|
0.9
|
|
Granzyme B
|
>0 (n = 11) vs. = 0(n = 19)
|
80% vs. 68%
|
0.46
|
|
Peritumoral immune cells in lymphatic tissue of metastatic nodes
|
|
CD3
|
>204.5 (n = 13) vs. ≤ 204.5 (n = 13)
|
66.7% vs. 80.8%
|
0.25
|
|
CD8
|
> 37.5 (n = 12) vs. ≤ 37.5 (n = 12)
|
72.7% vs. 76.4%
|
0.53
|
|
FoxP3
|
> 44 (n = 11) vs. ≤ 44 (n = 12)
|
90.9% vs. 62.3%
|
0.18
|
|
CD20
|
> 192 (n = 11) vs. ≤ 192 (n = 11)
|
100% vs. 63.6%
|
0.039
|
|
CD68
|
> 5.5 (n = 13) vs. ≤ 5.5 (n = 13)
|
76.9% vs. 81.5%
|
0.5
|
|
Granzyme B
|
>0 (n = 15) vs. = 0 (n = 15)
|
78.6% vs.67.3%
|
0.65
|
|
Immune cells in uninvolved regional lymph nodes
|
|
CD3
|
>183 (n = 15) vs. ≤ 183 (n = 16)
|
75.0% vs. 73.3%
|
0.675
|
|
CD8
|
>88 (n = 15) vs. ≤ 88 (n = 16)
|
84.6% vs. 65.6%
|
0.337
|
|
FoxP3
|
>49 (n = 15) vs. ≤ 49 (n = 16)
|
78.6% vs. 71.1%
|
0.905
|
|
CD20
|
>147 (n = 15) vs. ≤ 147 (n = 16)
|
79% vs. 68.6%
|
0.779
|
|
CD68
|
>4 (n = 12) vs. ≤ 4 (n = 17)
|
75.8% vs. 68.8%
|
0.424
|
|
Granzyme B
|
>0 (n = 13) vs. = 0 (n = 15)
|
73.3% vs.68.8%
|
0.939
|
